SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1.78 |
| Enterprise Value ($M) | -4.36 |
| Book Value ($M) | 4.74 |
| Book Value / Share | 3.14 |
| Price / Book | 0.38 |
| NCAV ($M) | 4.74 |
| NCAV / Share | 2.32 |
| Price / NCAV | 0.38 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.38 |
| Return on Assets (ROA) | -1.54 |
| Return on Equity (ROE) | -1.76 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.44 |
| Current Ratio | 3.44 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 6.69 |
| Assets | 6.69 |
| Liabilities | 1.95 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 9.99 | -54.82 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 4,031 | 44,138 | 9.13 | |
| 11,420 | 77,622 | 14.71 | |
| 170,143 | 544,223 | 31.26 | |
| 7,476 | 19,922 | 37.53 | |
| 7,078 | 49,942 | 14.17 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| DERM – Journey Medical Corporation | DMAC – DiaMedica Therapeutics Inc. |
| DNTH – Dianthus Therapeutics, Inc. | DRRX – DURECT Corporation |
| DRUG – Bright Minds Biosciences Inc. |
Financial data and stock pages provided by
Fintel.io